Placeholder Banner

Adopting foreign price controls “prevents investors from being able to invest, and inventors from being able to invent.”

February 3, 2020
Media Contact

In a new video, Alex Karnal, a life science investor and partner at Deerfield Management, shares why investing in new cures and treatments is personal, and he explains how President Trump’s plan to import foreign price controls would have an “absolutely chilling” effect on investments in transformational, life-saving therapies. 


“President Trump, we have got to lower drug prices at the pharmacy counter right now. In order to do that, we need four key groups to come together … and derive a holistic solution to treat the disease versus using foreign reference pricing as a scheme to focus on a single symptom.”

To learn more about the flaws of importing foreign price controls, visit

Additional resources:


Discover More
The Biotechnology Innovation Organization (BIO) this week hosted a productive virtual summit intended to foster collaboration among key government agencies and biopharmaceutical innovators with one goal: eradicating Covid-19. The two-day virtual…
Companies are Coming Together to Achieve Shared Goal of Eradicating the Virus  Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) underscored the industry’s commitment…
The Securities and Exchange Commission (SEC) has adopted regulatory changes to provide small public companies with a temporary exemption from Sarbanes-Oxley 404(b) compliance. 404(b) requires public companies to report on the internal controls they…